Clinical trials: Venous Thromboembolic Event
Cancer, Rivaroxaban
Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
The Valeria trial will provide high-quality evidence regarding the efficacy and safety of oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in comparison with standard parenteral enoxaparin.
- Conditions
- Cancer, Rivaroxaban, Venous Thromboembolism, Thromboprophylaxis
- Trial name
- VALERIA (NCT04999176)
- Testing
- Rivaroxaban, Enoxaparin
- Where
- Brazil
- Volunteers
- 440 people
- Sponsor
- André Luiz Malavasi Longo de Oliveira
Prevention, Venous Thromboembolism
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Trial name
- NCT01181167
- Testing
- edoxaban, enoxaparin sodium
- Where
- 2 sites in Japan
- Volunteers
- 610 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Primary Total Hip and Knee Arthroplasty
Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty
This is a prospective, randomized study from pre-surgery to 6 weeks post-surgery designed to detect changes in coagulability following elective total knee and hip arthroplasty.
- Trial name
- NCT01809054
- Testing
- Arixtra, Pneumatic compression stockings, Aspirin
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- LifeBridge Health
Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation
Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor
Background : pregnancy and postpartum period are times of increased risk for deep vein thrombosis (DVT). The incidence of venous thromboembolic disease (VTE) during pregnancy is estimated at 1-2 per 1,000, and this risk increases…
- Conditions
- Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation, Pregnancy, Postpartum
- Trial name
- POSTPART AS5-2 (NCT07342127)
- Testing
- Retrospective collection of health data, Phone call to every participant
- Where
- 2 sites in France
- Volunteers
- 86 people
- Sponsor
- Hospices Civils de Lyon
Venous Thromboembolism, Fetal Death
Fetal Loss in Women With Unprovoked Thromboembolism (FLUTE)
The purpose of this study is to determine the risk of fetal loss in women with unprovoked venous thromboembolism (VTE) who do not have identifiable inherited thrombophilia compared with women who have the diagnosis of venous…
- Trial name
- NCT00149357
- Testing
- Thrombophilia Testing
- Where
- 5 sites in Australia, Canada
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- McMaster University
Prostate Cancer, Venous Thromboembolism
PREvention of VENous ThromboEmbolism Following Radical Prostatectomy
The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous…
- Conditions
- Prostate Cancer, Venous Thromboembolism, Lymphocele After Surgical Procedure, Deep Venous Thrombosis
- Trial name
- PREVENTER (NCT03006562)
- Testing
- Subcutaneous Heparin
- Where
- United States
- Volunteers
- 501 people
- Sponsor
- Johns Hopkins University
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-INCLINE (NCT07430956)
- Testing
- REGN7508, REGN9933
- Where
- 44 sites in United States, Canada
- Volunteers
- 2,628 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism, Ovarian Cancer
Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.
- Trial name
- NCT04352439
- Testing
- Aspirin
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Duke University
Venous Thromboembolism
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04736719
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 19,002 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism
Venous Thromboembolism During COVID-19 Pandemic: Evaluation of the Association With the Vaccine and COVID-19 Infection
Observational, spontaneous, retrospective, multicenter national study for adult patients, not hospitalized, attending the Thrombo-Embolic Emergency Clinic of the Angiology and Coagulation Disorders Unit (SSD Angiologia e Malattie…
- Trial name
- NCT06806800
- Where
- Italy
- Volunteers
- 16,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Intracranial Thrombosis
Modern Ultrasound Techniques in the Evaluation of Cerebral Venous Sinuses in Neonates
Our overall aim is to examine if ultrasound is as accurate as MRI and/or CT in the evaluation of dural venous sinuses. We hypothesize that sonography will be accurate (accuracy >80%) for diagnosing specific anatomic findings of…
- Trial name
- NCT00555932
- Testing
- Ultrasound
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- The Hospital for Sick Children
Pulmonary Embolism
Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.
Rational: After 3 or 6 months of oral anticoagulation for an episode of acute venous thromboembolism (VTE), the risk of recurrent VTE is high (10 to 15% per year) in comparison with a low risk of recurrence if VTE was provoked by…
- Trial name
- PADIS EP (NCT00740883)
- Testing
- warfarin
- Where
- France
- Volunteers
- 374 people
- Sponsor
- University Hospital, Brest
Recruiting
VTE Risk Prevention System Based on Big Data Analysis and Multimodule System
Venous thromboembolism (VTE) is one of the most common complications in perioperative period and the most common cause of postoperative death. VTE includes deep vein thrombosis (DVT) and acute pulmonary thromboembolism (PTE).
- Trial name
- NCT05969951
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Shengjing Hospital
Pulmonary Embolism, Proximal Deep Vein Thrombosis
Six Years of Follow-up After Idiopathic Venous Throbmoembolism
Beyond the first 6 months of anticoagulation, patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after stopping anticoagulations.
- Trial name
- Padis-Ext (NCT02884934)
- Where
- 10 sites in France
- Volunteers
- 409 people
- Sponsor
- University Hospital, Brest
Arterial Thromboembolism, Venous Thromboembolism
Aspiration Thrombectomy Using the Symphony or Prodigy System
The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.
- Conditions
- Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- CLEAR-IT (NCT07350499)
- Testing
- Prodigy Thrombectomy System, Symphony Thrombectomy System
- Where
- 13 sites in United States
- Volunteers
- 750 people
- Sponsor
- Imperative Care, Inc.
Venous Thromboembolism, Renal Impairment
Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function
This is a clinical trial including non-surgical patients, 70 years of age or older, with renal impairment requiring pharmacological venous thromboembolism prevention during hospitalization.
- Trial name
- NCT03158792
- Testing
- Enoxaparin 20Mg/0.2mL Prefilled Syringe, Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml
- Where
- Lebanon
- Volunteers
- 32 people
- Sponsor
- Lebanese American University
Venous Thromboembolism
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)
This trial seeks to assess the feasibility of a full-scale, double-blind, placebo-controlled, randomized trial assessing whether low-dose colchicine (0.5 mg daily) reduces the risk of post-thrombotic syndrome (PTS) in patients…
- Trial name
- NCT06440694
- Testing
- Colchicine 0.5 mg po
- Where
- 4 sites in Canada
- Volunteers
- 150 people
- Sponsor
- Ottawa Hospital Research Institute
Thrombosis, Venous
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by…
- Trial name
- FONDACAST (NCT00843492)
- Testing
- Fondaparinux sodium, Nadroparin
- Where
- 122 sites in France, Germany and 4 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Treatment of Venous Thromboembolism in Cancer Patients
A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)
Patients with cancer are more likely than those without cancer to develop blood clots (deep vein thrombosis and pulmonary embolism), which are treated using blood thinners (anticoagulants).
- Trial name
- NCT05112666
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), other DOACs, LMWH
- Where
- United Kingdom
- Volunteers
- 2,601 people
- Sponsor
- Bayer
Venous Thromboembolism (VTE)
Diagnostic and Prognostic Prediction Models for Chinese Patients With Venous Thromboembolism
The objective of this proposal is to develop and validate diagnostic and prognostic (including short-term and long-term prognoses) prediction models for patients with venous thromboembolism (VTE) in China.
- Trial name
- NCT03802929
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Ya-Wei Xu